期刊文献+

高效液相色谱法测定维格列汀R型异构体的含量

Determination of vildagliptin R-isomer by HPLC
下载PDF
导出
摘要 目的:建立维格列汀R型异构体含量的高效液相色谱检测方法。方法:采用高效液相色谱(HPLC)法测定,色谱柱为ChiralpakIC(250mm×4.6mm,5μm);流动相为乙醇-正己烷-叔丁基胺(90∶10∶0.1);流速为0.7ml/min;柱温为25℃;检测波长210nm。结果:维格列汀与其R型异构体峰分离良好,异构体在0.4~2.4μg/ml浓度范围内,浓度与峰面积呈良好的线性关系,异构体的定量限为4.0ng,检测限为1.3ng。结论:该方法简便易行,灵敏度高,可用于维格列汀R型异构体含量的检测。 Objective: In this paper, we established a high performance liquid chromatograph method for determining of the R- enantiomer content of vildagliptin. Methods: The high performance liquid chromatography was used. The determination was performed on Chiralpak IC(250 mm×4.6 mm,5 μm)column, and the mobile phase was composed of solution of ethanol : n-hexane: tert-butylamine (90∶10∶0.1). The flow rate was 0.7 ml/min, the column temperature was 25 ℃ and the detection wavelength of 210 nm. Results: The peaks of vildagliptin and its R- isomer were well separated. Within the range of 0.4~2.4 μg/ml, the concentration of the R- isomer showed a good linear relationship between the concentration and the peak area. The limit of quantification was 4.0 ng, and the limit of detection was 1.3 ng. Conclusion: The established method was simple, feasible and highly sensitive. It can be used for determining the R- enantiomer content of vildagliptin.
作者 刘宏果 张之奎 Liu Hongguo;Zhang Zhikui(Shijiazhuang Penghai Pharmaceutical Corporation, Shijiazhuang, Hebei 050600)
出处 《天津药学》 2019年第4期16-18,共3页 Tianjin Pharmacy
基金 河北省开发区“3·20”人才支持项目(冀才[2016]4号) 石家庄市第二批“高层次人才支持计划”人选项目(石字[2018]27号) 行唐县科学技术研究与发展计划项目(No.2018SYD201)
关键词 维格列汀 R型异构体 高效液相色谱法 vildagliptin R- enatiomer HPLC
  • 相关文献

参考文献2

二级参考文献38

  • 1夏玲红.治疗糖尿病的新药西他列汀[J].中国新药杂志,2007,16(12):979-981. 被引量:26
  • 2PRATLEY RE, SALSALI A, MATFIN G. Inhibition of dipeptidyl peptidase-4 with vildagliptin : a potential new treatment for type 2 diabetes[ J]. Br J Diabetes Vasc Dis,2006,6(4) : 150 - 156.
  • 3VILLHAUER EB, BRINKMAN JA, NADERI GB, et al. 1-[ [ ( 3- hydroxy-1 - adamantyl ) amino ] acetyl ] -2-cyano-( S ) - pyrrolidine : a potent, selective, and orally bioavailable dipeptidyl peptidase Ⅳ inhibitor with antihyperglycemic properties[ J ]. J Med Chem, 2003,46 ( 13 ) :2774 - 2789.
  • 4MARGUET D, BAGGIO L,KOBAYASHI,et al. Enhanced insulin secretion and inproved glucose tolerance in mice lacking CD26 [ J ]. Proc Natl Acad Sci USA ,2000,97 ( 12 ) :6874 - 6879.
  • 5NAGAKUBA T, YASUDA N,YAMAZAKI K,et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptldyl peptidase Ⅳ- deficient Fischer rats [ J ]. Biochem Biophys Res Commun,2001,284(2 ) :501 - 506.
  • 6HE Y,BALCH A, CAMPESTRINI J, et al. Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes [ J ]. Clin Pharmacol Ther,2005,77 ( 2 ) :56.
  • 7HE YL,SABO R,CAMPESTRINI J ,et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase Ⅳ ( DDP-4 ) inhibitor vildagliptin [ J ]. Eur J. Clin Pharm,2007, 63(7) :677 -686.
  • 8PRATLEY RE, JAUFFRET-KAMEL S, GALBREATH E,et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes [ J ]. Horm Metab Res ,2006,38 ( 6 ) :423 - 428.
  • 9RISTIC S, BYIERS S, FOLEY J,et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin ( LAF237 ) dose response [ J ]. Diabetes Obes Metab,2005,7 ( 6 ) : 692 - 698.
  • 10BOSI E,CAMISASCA RP,COLLOBER C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin [ J ]. Diabetes Care, 2007,30(4) :890 - 895.

共引文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部